|
|
Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group.
|
|
|
06.10.07 |
S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota, USA
|
 related articles |
THE INTERNATIONAL MYELOMA FOUNDATION SAYS ECOG RESULTS COULD IMPROVE SURVIVAL WHILE REDUCING SIDE EFFECTS FOR MANY PATIENTS
Mayo Clinic Press Release: Multiple Myeloma Clinical Trial Closes Early Due to Superior Results of Comparative Treatment
National Cancer Institute Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
National Institutes of Health Press Release: Low-dose Steroid Combined with Lenalidomide Prolongs Survival Compared with High-dose Steroid for Multiple Myeloma Treatment
Understanding Thalidomide Therapy
Understanding Dexamethasone and Other Steroids
|
|
|
|
Findings Challenge Traditional Assumption that More-Is-Better when Treating Cancer |
|
|
|
|
|
Mayo Clinic Cancer Center announced today that a multiple myeloma clinical trial has shown a significant improvement in survival with lenalidomide plus low-dose dexamethasone therapy compared to lenalidomide plus high-dose dexamethasone. |
|
|
|
|
|
The clinical trial was sponsored by the National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). |
|
|
|
|
Learn more about Revlimid® (lenalidomide), approved by the FDA for use in myeloma. |
|
|
|
|
Using thalidomide to treat myeloma is a new idea, but thalidomide itself has been studied for many decades. |
|
|
|
|
What dexamethasone is, how it works, possible side effects, and more. |
|
|
back
print